Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement
Matthias Gückenberger(University Hospital of Zurich), David A. Palma(Western University), Corinne Faivre‐Finn(University of Manchester), Sameera Kumar(Fox Chase Cancer Center), Yolande Lievens(Ghent University Hospital), Puneeth Iyengar(Memorial Sloan Kettering Cancer Center), Joachim Widder(Comprehensive Cancer Center Vienna), Karin Lindberg(Karolinska University Hospital), Jeffrey D. Bradley(University of Pennsylvania), George Rodrigues(London Health Sciences Centre), Ramesh Rengan(University of Pennsylvania), Claus Belka(LMU Klinikum), Sara Ramella(Università Campus Bio-Medico), Megan E. Daly(University of California Davis Medical Center), Andrea Bezjak(Princess Margaret Cancer Centre), Michael Flentje(Universitätsklinikum Würzburg), Elizabeth Gore(Medical College of Wisconsin), Andreas Rimner(University Medical Center Freiburg), Brian D. Kavanagh(University of Colorado Denver), Rafał Dziadziuszko(Gdańsk Medical University), Umberto Ricardi(Azienda Ospedaliero Universitaria San Giovanni Battista), Steven E. Schild(Mayo Clinic Hospital), Charles B. Simone(New York Proton Center), Ben J. Slotman(Vrije Universiteit Amsterdam), Martin Stuschke(Essen University Hospital), Suresh Senan(Amsterdam Neuroscience), Kristin Higgins(Emory University), Sue S. Yom(University of California, San Francisco), Fiona McDonald(Royal Marsden Hospital), G.M. Videtic(Cleveland Clinic Lerner College of Medicine), D Deruysscher(Maastricht University), C. Le Péchoux(Institut Gustave Roussy)
Cited by 227
Related Papers
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k